Skip to content
★ Sign in to follow
ADARx Pharmaceuticals, Inc. logo

ADARx Pharmaceuticals, Inc. Stock: price and insider trades · United States

US·Mcap US$1.8BHealth Care

3 insiders bought €29.2M of shares over the last 90 days, the latest by Chimovits Erez, filed 30 Sept 2026.

Insider Decl.
43
Thresholds
n/a
Buy Volume
€29M
5 ops. · all time
Sell Volume
n/a
n/a

Who traded when

BuySale
Carl L. Gordon2 buys
Simeon George2 buys
Erez Chimovits1 buy

Since the insiders bought

  • Filed 30 Sept 2026 · 48 days ago · €918k
    -12.3%
    Entry US$19.54 · Close 21 Oct 2026 US$17.13
  • Filed 30 Sept 2026 · 48 days ago · €4.5M
    -12.3%
    Entry US$19.54 · Close 21 Oct 2026 US$17.13
  • Filed 29 Sept 2026 · 49 days ago · €8.8M
    -14.1%
    Entry US$19.94 · Close 21 Oct 2026 US$17.13

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Analyst consensus: bullish or bearish?

Analysts rate ADARx Pharmaceuticals, Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$34.25.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Financial data

as of FY 2025

FY ended December 2025 · cache

US$17.13
Analyst consensus
4 analysts
Strong buy
US$32.00Target US$34.25(+100%)US$38.00
Income statement
RevenueUS$3.4M
EBITDA-US$86M-2495% margin
Net income-US$73.1M-2119.1% margin
Valuation
PER (forward)-11.3x
Balance sheet & cash
Market capUS$1.8B
Total debtUS$7.7M
Free Cash FlowUS$259.4M
Debt / Equity6%
Profitability & ownership
% insiders41.8%
% institutions44.8%
Last declaration on 30 September 2026

T+90 is the date 90 days after the filing, the exit horizon used to measure each purchase.

Declarations43 total
  • ▲
    DirectorExecutives
    1M USD37SEC
    61,516 shares@ US$17.00100.0% of flowCommon StockSEC:0000947871-26-000912:4
    Canonical exit: 27 Dec 2026 (T+90)
  • ●
    DirectorExecutives
    0SEC
    10,690,530 sharesCommon StockSEC:0000947871-26-000911:0
  • ●
    DirectorExecutives
    0SEC
    2,000,962 sharesCommon StockSEC:0000947871-26-000911:1
  • ●
    DirectorExecutives
    0SEC
    769,601 sharesCommon StockSEC:0000947871-26-000911:2
  • ●
    DirectorExecutives
    0SEC
    564,187 sharesCommon StockSEC:0000947871-26-000911:3
  • ▲
    DirectorExecutives
    5M USD32SEC
    300,249 shares@ US$17.0031.6% of flowCommon StockSEC:0000947871-26-000911:4
    Canonical exit: 27 Dec 2026 (T+90)
  • ●
    DirectorExecutives
    0SEC
    7,127,019 sharesCommon StockSEC:0000947871-26-000911:5
  • ●
    DirectorExecutives
    0SEC
    1,333,975 sharesCommon StockSEC:0000947871-26-000911:6
  • ●
    DirectorExecutives
    0SEC
    513,067 sharesCommon StockSEC:0000947871-26-000911:7
  • ●
    DirectorExecutives
    0SEC
    256,448 sharesCommon StockSEC:0000947871-26-000911:8
  • ▲
    DirectorExecutives
    10M USD35SEC
    588,235 shares@ US$17.0061.9% of flowCommon StockSEC:0000947871-26-000911:10
    Canonical exit: 27 Dec 2026 (T+90)
  • ●
    Related company / holdingExecutives
    0SEC
    10,690,530 sharesCommon StockSEC:0000947871-26-000910:0
  • ●
    Related company / holdingExecutives
    0SEC
    2,000,962 sharesCommon StockSEC:0000947871-26-000910:1
  • ●
    Related company / holdingExecutives
    0SEC
    769,601 sharesCommon StockSEC:0000947871-26-000910:2
  • ●
    Related company / holdingExecutives
    0SEC
    564,187 sharesCommon StockSEC:0000947871-26-000910:3
  • ●
    Related company / holdingExecutives
    0SEC
    7,127,019 sharesCommon StockSEC:0000947871-26-000910:5
  • ●
    Related company / holdingExecutives
    0SEC
    1,333,975 sharesCommon StockSEC:0000947871-26-000910:6
  • ●
    Related company / holdingExecutives
    0SEC
    513,067 sharesCommon StockSEC:0000947871-26-000910:7
  • ●
    Related company / holdingExecutives
    0SEC
    256,448 sharesCommon StockSEC:0000947871-26-000910:8
  • ●
    DirectorExecutives
    0SEC
    513,067 sharesCommon StockSEC:0000947871-26-000912:2
  • ●
    DirectorExecutives
    0SEC
    256,448 sharesCommon StockSEC:0000947871-26-000912:3
  • ●
    DirectorExecutives
    0SEC
    1,333,975 sharesCommon StockSEC:0000947871-26-000912:1
  • ●
    DirectorExecutives
    0SEC
    7,127,019 sharesCommon StockSEC:0000947871-26-000912:0
  • ▲
    DirectorExecutives
    10M USD29SEC
    592,593 shares@ US$17.0058.8% of flowCommon StockSEC:0001193125-26-408061:3
    Canonical exit: 27 Dec 2026 (T+90)
  • ●
    DirectorExecutives
    0SEC
    1,538,691 sharesCommon StockSEC:0001193125-26-408061:4

25 of 43 declarations

About ADARx Pharmaceuticals, Inc.

All of the activity at ADARx Pharmaceuticals, Inc. falls on one day. On September 28, 2026, 5 purchases are recorded for EUR 29.2 million, from 3 filers, published on September 29 and 30, 2026: EUR 8.8 million and EUR 6.2 million for Simeon George (Director), and EUR 8.8 million for Carl L. Gordon (Director). The median purchase is EUR 6,192,219, and 5 filings belong to cluster purchases.

The record has 43 filings from 6 filers, all published in 2026 with a median delay of 2 days. 38 are neither purchases nor sales: Orbimed Advisors LLC (Director) filed 8, SR One Capital Management, LLC (10% Owner) 6 and LAV Biosciences Fund V, L.P. (10% Owner) 6. Carl L. Gordon filed 10, 2 of them purchases, and Simeon George filed 8, also 2 purchases. No sale is recorded.

Read moreShow less

This US healthcare company, listed on Nasdaq and valued at USD 1.9 billion, has 41.8% of its capital held by insiders. The last 12 months match the whole record: 43 filings, 5 purchases.

Written on 22 October 2026 from the filings and market data available that day. Live figures are in the blocks above.

The weekly insider digest, free

One email on Fridays: the insider clusters and single-name signals worth reading. Unsubscribe in one click.